UY40794A - Formas cristalinas de (s)-afoxolaner - Google Patents

Formas cristalinas de (s)-afoxolaner

Info

Publication number
UY40794A
UY40794A UY0001040794A UY40794A UY40794A UY 40794 A UY40794 A UY 40794A UY 0001040794 A UY0001040794 A UY 0001040794A UY 40794 A UY40794 A UY 40794A UY 40794 A UY40794 A UY 40794A
Authority
UY
Uruguay
Prior art keywords
crystalline forms
afoxolaner
crystalline
forms
compositions
Prior art date
Application number
UY0001040794A
Other languages
English (en)
Inventor
Johannes GORTER DE VRIES Roelof
Bruno Baillon
Sylvaine Lafont
Gay De Saint Michel Myriam
Kozlovic Stéphane
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of UY40794A publication Critical patent/UY40794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Secondary Cells (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas cristalinas del compuesto de fórmula (la) y procesos de elaboración de las formas cristalinas. También se proveen composiciones que comprenden las formas cristalinas y métodos de uso de dichas formas cristalinas.
UY0001040794A 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner UY40794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
UY0001037665A UY37665A (es) 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner

Publications (1)

Publication Number Publication Date
UY40794A true UY40794A (es) 2024-07-15

Family

ID=62092252

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001040794A UY40794A (es) 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner
UY0001037665A UY37665A (es) 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001037665A UY37665A (es) 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner

Country Status (22)

Country Link
US (2) US10662163B2 (es)
EP (1) EP3606911A1 (es)
JP (1) JP7222909B2 (es)
KR (1) KR102612648B1 (es)
CN (2) CN111032634B (es)
AR (1) AR111412A1 (es)
AU (1) AU2018250304B2 (es)
CA (1) CA3059114A1 (es)
CL (1) CL2019002840A1 (es)
CO (1) CO2019011980A2 (es)
EA (1) EA201992360A1 (es)
IL (1) IL269792B (es)
MD (1) MD20190080A2 (es)
MX (1) MX2019011931A (es)
MY (1) MY188420A (es)
PH (1) PH12019502277A1 (es)
SG (1) SG11201909229SA (es)
TW (1) TWI782976B (es)
UA (1) UA125727C2 (es)
UY (2) UY40794A (es)
WO (1) WO2018187623A1 (es)
ZA (1) ZA201906464B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner
WO2021254445A1 (zh) * 2020-06-19 2021-12-23 东莞市东阳光仿制药研发有限公司 一种gaba抑制剂的晶型及其制备方法
AU2021311722A1 (en) 2020-07-24 2023-02-02 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
CN117486869A (zh) * 2023-11-06 2024-02-02 北京康立生医药技术开发有限公司 一种眼科治疗药物新的制备方法
CN118536571B (zh) * 2024-05-31 2025-02-25 北京无问芯穹科技有限公司 一种构建扩散变换器模型的方法、系统、设备及存储介质
WO2025257633A1 (en) 2024-06-12 2025-12-18 Boehringer Ingelheim Vetmedica Gmbh Long-acting castor oil-containing injectable formulations and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) * 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI649303B (zh) * 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
RS54677B1 (sr) 2010-05-27 2016-08-31 E. I. Du Pont De Nemours And Company Kristalni oblici 4-[5-[3-hloro-5-(trifluorometil)fenil]-4,5 -dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida
PL3172964T3 (pl) * 2011-09-12 2021-03-08 Boehringer Ingelheim Animal Health USA Inc. Kompozycje przeciwpasożytniczne zawierające izoksazolinową substancję czynną, sposób i ich zastosowania
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
EA036272B1 (ru) * 2015-04-08 2020-10-21 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение
DK3440062T3 (da) 2016-04-06 2022-01-03 Boehringer Ingelheim Animal Health Usa Inc Fremgangsmåde til fremstillingen af enantiomerisk berigede isoxazolinforbindelser - krystallinsk toluensolvat af (s)-afoxolaner
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner

Also Published As

Publication number Publication date
AU2018250304B2 (en) 2022-03-03
PH12019502277A1 (en) 2020-09-14
BR112019021072A2 (pt) 2020-05-12
TW201841895A (zh) 2018-12-01
AR111412A1 (es) 2019-07-10
US10662163B2 (en) 2020-05-26
ZA201906464B (en) 2021-08-25
CL2019002840A1 (es) 2020-01-10
NZ757869A (en) 2024-11-29
JP7222909B2 (ja) 2023-02-15
CN120172925A (zh) 2025-06-20
UY37665A (es) 2018-10-31
TWI782976B (zh) 2022-11-11
MD20190080A2 (ro) 2020-04-30
AU2018250304A1 (en) 2019-10-31
CO2019011980A2 (es) 2020-02-18
CN111032634B (zh) 2025-04-11
MY188420A (en) 2021-12-08
WO2018187623A8 (en) 2019-10-24
KR20190136055A (ko) 2019-12-09
IL269792B (en) 2022-04-01
US20180354917A1 (en) 2018-12-13
EA201992360A1 (ru) 2020-09-02
JP2020513010A (ja) 2020-04-30
KR102612648B1 (ko) 2023-12-11
CN111032634A (zh) 2020-04-17
WO2018187623A1 (en) 2018-10-11
SG11201909229SA (en) 2019-11-28
US11130739B2 (en) 2021-09-28
US20200270219A1 (en) 2020-08-27
EP3606911A1 (en) 2020-02-12
MX2019011931A (es) 2020-01-13
UA125727C2 (uk) 2022-05-25
IL269792A (en) 2019-11-28
CA3059114A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
UY40794A (es) Formas cristalinas de (s)-afoxolaner
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
MX380753B (es) Lactamas bicíclicas y métodos de uso de las mismas.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
CO2019006687A2 (es) Polimorfos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CO2019006673A2 (es) Polimorfos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2021006977A (es) Anellosomas y metodos de uso.
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX370791B (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
NI202000042A (es) Polimorfos
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
MX379649B (es) Derivados de azetidina para formacion de imágenes de tau.
PY1508111A (es) Polimorfos
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20251226